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Glycoprotein B (gB) is a conserved, essential component of gammaherpes virions and so
potentially vulnerable to neutralization. However, few good gB-specific neutralizing antibodies
have been identified. Here, we show that murid herpesvirus 4 is strongly neutralized by mAbs that
recognize an epitope close to one of the gB fusion loops. Antibody binding did not stop gB
interacting with its cellular ligands or initiating its fusion-associated conformation change, but did
stop gB resolving stably to its post-fusion form, and so blocked membrane fusion to leave virions
stranded in late endosomes. The conservation of gB makes this mechanism a possible general
route to gammaherpesvirus neutralization.
INTRODUCTION
Vaccination provides a cornerstone of antiviral intervention.
However, herpesviruses routinely transmit from immuno-
competent hosts (Klein, 1989; Gorman et al., 2006), and
while vaccination can dampen down their acute infections it
has not prevented their persistence or transmission (Baigent
et al., 2006). Neutralizing antibodies are a key component of
antiviral immunity (Zinkernagel & Hengartner, 2006), so
limited infection control by natural and vaccine-primed
immune responses suggests that in vivo herpesvirus
neutralization is not easily achieved.
Murid herpesvirus 4 (MuHV-4), a close relative of the
Kaposi’s sarcoma-associated herpesvirus (Efstathiou et al.,
1990; Virgin et al., 1997), provides a way to analyse how
gammaherpesviruses and antibodies interact. Immune sera
block MuHV-4 binding to fibroblasts (Gill et al., 2006), but
promote myeloid cell infection via IgG Fc receptor binding
(Rosa et al., 2007; Smith et al., 2007) and poorly block host
entry (Gillet et al., 2007a). Therefore, good in vivo
neutralization may have to target processes downstream
of binding such as membrane fusion.
Fusion requires the conserved virion glycoproteins B (gB)
and H (gH) (Spear & Longnecker, 2003; Hutt-Fletcher,
2007). A fusogenic role for gB is supported by structural
homology between herpesvirus gBs (Heldwein et al.,2 0 0 6 ;
Backovic et al., 2009) and the post-fusion vesicular
stomatitis virus glycoprotein G (VSV-G) (Roche et al.,
2006). The MuHV-4 gB undergoes a marked antigenic
change when virion capsids are released from late
endosomes: some gB-specific mAbs (archetype BN-1A7)
recognize only extracellular virions; others (archetype
MG-1A12) recognize only those in late endosomes;
relatively few recognize both (Gillet et al., 2008a). The
gB of extracellular virions must be pre-fusion. At least
some of that in late endosomes must be post-fusion, and
the uniformity of the virion switch from BN-1A7
+MG-
1A12
2 to BN-1A7
2MG-1A12
+ in late endosomes implies
that all gB becomes post-fusion. Treating cells with
concanamycin A to raise the endosomal pH blocks both
the gB conformation switch and capsid release. However,
low pH alone triggers neither (Gillet et al.,2 0 0 8 a ) .T h u s ,
the fusion mechanism seems to involve pH but is not
simply pH driven.
gB-directed neutralization has been explored extensively
for human cytomegalovirus (HCMV) (Cranage et al.,
1986; Ohlin et al., 1993; Speckner et al., 1999). For both it
and herpes simplex virus (HSV), gB-specific neutralizing
mAbs can block virus penetration (Highlander et al., 1988;
Navarro et al., 1993). Such neutralization is much less
readily achieved for MuHV-4 (Gillet et al., 2006).
However, HSV and HCMV neutralization is generally
defined as 50% plaque reduction. The less uniformly lytic
replication of MuHV-4 (May et al., 2004) makes such
minor reductions hard to reproduce; such reductions can
also be achieved by virion cross-linking. Therefore, our
more stringent (although equally arbitrary) cut-off for
significant MuHV-4 neutralization is 80% plaque reduc-
tion. It cannot be assumed that 50% neutralization will
become 80% with more antibody. For example, O-
glycosylation limits neutralization directed against the
MuHV-4 gB N terminus regardless of antibody dose
(Gillet & Stevenson, 2007a). Thus, weak neutralization
may be noted more often for HCMV and HSV than for
MuHV-4. A supplementary figure is available with the online version of this paper.
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neutralization epitopes map to prominent features of
post-fusion gB (Heldwein et al., 2006). Because HSV and
HCMV fuse in vitro with the plasma membrane (Spear &
Longnecker, 2003), some post-fusion gB epitopes might
become accessible to extracellular antibody before actual
capsid release. The endocytic infection of MuHV-4 (Gill
et al., 2006) by contrast segregatesfusion fromfree antibody,
and mAbs (n.30) specific for post-fusion gB – that is those
recognizing virion gB only after capsid release – do not
neutralize (our unpublisheddata). Thus, endocytic infection
may increase the difficulty of gB-directed neutralization.
Where gB-directed MuHV-4 neutralization does occur,
the gB N terminus is a frequent target (Gillet et al.,2 0 0 6 ) .
This is consistent with results from other herpesviruses
(Ohlin et al., 1993; Akula et al., 2002; Okazaki et al.,
2006). The MuHV-4 gB N terminus is redundant for
infectivity, so antibodies binding here must neutralize by
steric hindrance and have been effective only as penta-
meric IgMs (Gillet & Stevenson, 2007a). Several other
MuHV-4 gB neutralization epitopes show the same
dependence on high antibody avidity (Gillet et al.,
2008a). Such neutralization has limited relevance to
vaccination, where most antibodies are IgG. However,
we have recently identified two potently neutralizing
MuHV-4 gB-specific IgGs. While immunization with
recombinant gB boosted neutralization in only a minority
of carrier mice and did not elicit neutralizing antibodies in
naive mice (May & Stevenson, 2010), a more refined
immunogen that selectively presents key gB epitopes
might be more effective. In order to develop such an
approach, we analysed here how IgG-mediated gB-
directed neutralization works.
RESULTS
Mapping a potent gB-specific neutralization epitope
A large-scale screen of B-cell hybridomas from MuHV-4
carrier mice identified SC-9A5 (IgG3) and SC-9E8 (IgG2a)a s
potent neutralizing mAbs (Fig. 1a). SC-9A5 was consistently
more effective at low dose, whereas SC-9E8 was more
effective at high dose, possibly reflecting an influence of
isotype on mAb binding (Greenspan & Cooper, 1995).
Unlike mAb MG-2C10 which is blocked from recognizing
normal murine mammary gland (NMuMG) cell-derived
virions by O-linked glycans (Gillet & Stevenson, 2007a),
SC-9A5 and SC-9E8 neutralized both NMuMG and baby
hamster kidney (BHK-21) cell-derived virions (Fig. 1b).
Note that while MG-2C10 has a lower ID50, SC-9A5/SC-9E8
show much better maximal neutralization.
Like all our mAbs that recognize extracellular virion gB,
SC-9A5 and SC-9E8 recognized the gB N-terminal half
(gB-N) (Fig. 1c). Blocking experiments (Fig. 1d) estab-
lished that the SC-9E8 epitope was distinct from that of
MG-2C10 (Gillet et al., 2006) or another neutralizing IgM,
BH-6B5 (Gillet et al., 2008a), but overlapped that of
SC-9A5. The N-terminal gB domains include its putative
fusion loops (Heldwein et al., 2006; Backovic et al., 2007;
Hannah et al., 2009), which are analogous to the fusion
loops of VSV-G (Roche et al., 2007). Fig. 1(e) compares the
HSV-1 gB structure (Heldwein et al., 2006) with that
predicted for MuHV-4. Residues identified as critical for
HSV fusion (Hannah et al., 2009) are shown, together with
analogous mutations we made in the MuHV-4 loops
(L1V1, L1V2, L1V3 and L2). Fig. 1(f) shows how these
mutations affected gB recognition by SC-9E8 and a control
mAb, BN-1A7. Mutating fusion loop 2 had no effect.
Mutations L1V1 and L1V2 around loop 1 substantially
reduced recognition by SC-9E8 without affecting BN-1A7.
A more precise loop 1 mutation (L1V3) affected neither.
Therefore, the SC-9E8 epitope was not fusion loop 1 itself –
not surprisingly because the fusion loops should not be
accessible on extracellular virions – but appeared to be
close to loop 1. It could involve the L1V1 and L1V2
mutation sites directly, or be affected by local conforma-
tion changes caused by the mutations.
The SC-9E8/SC-9A5 epitope is exclusive to pre-
fusion gB
That SC-9E8 and SC-9A5 recognize pre-fusion gB was
confirmed by staining virions bound to cells at 4 uC (Fig.
2a). Here gB must be pre-fusion, since MuHV-4 capsids
are released only after endocytosis. After a further 2 h
incubation at 37 uC, during which virions reach lysosomal-
associated membrane protein (LAMP-1)
+ late endosomes
and fuse, recognition by SC-9E8 and SC-9A5 was lost. This
pattern conformed to recognition by the pre-fusion
gB-specific mAb BN-1A7, and was opposite to that by
the post-fusion gB-specific mAb MG-1A12. When mem-
brane fusion was blocked by concanamycin A, gB
recognition by BN-1A7 was preserved and that by MG-
1A12 was prevented, indicating that gB remained in its pre-
fusion form. Recognition by SC-9E8 and SC-9A5 was also
preserved (Fig. 2b). Therefore, the SC-9E8/SC-9A5 epitope,
like that of BN-1A7, was specific to pre-fusion gB.
Neutralized virions bind to cells but cannot fuse
SC-9E8 and SC-9A5 concentrations that potently reduced
new viral eGFP expression failed to reduce cell binding by
virions physically tagged with eGFP (gM-eGFP) (Fig. 3a).
Indeed binding was increased, probably due to virion
cross-linking generating very high avidity particles. In
contrast, neutralization by immune sera or by heparin was
associated with reduced cell binding. Also SC-9A5 and
SC-9E8 neutralized both cell-bound and cell-free virions,
whereas immune serum was substantially less effective
against cell-bound virions (Fig. 3b). SC-9A5 and SC-9E8
further reduced MuHV-4 infection of IgG Fc receptor
+
RAW-264 cells, whereas immune serum reduced BHK-21
and NMuMG cells infections (Fig. 3c) but increased
RAW-264 cell infection – because FcR-dependent virion
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http://vir.sgmjournals.org 2021Fig. 1. (a) Virus neutralization by gB-specific mAbs SC-9A5 and SC-9E8. Bacterial artificial chromosome (BAC)
+ MuHV-4
(0.1 p.f.u. per cell) was incubated with gB-specific mAbs SC-9A5 (IgG3), SC-9E8 (IgG2a), BN-1A7 (IgG2a, non-neutralizing) or
MG-2C10 (IgM, neutralizing) before being added to BHK-21 cells. After overnight incubation (37 6C) in the presence of 100 mg
phosphonoacetic acid ml
”1 to prevent further virus spread, eGFP
+ cells were enumerated by flow cytometry and are shown relative
to untreated virus. Each point shows the mean±SEM of two experiments. By chi-squared test comparing the proportions of eGFP
+
andeGFP
”cells,mAbsSC-9A5andSC-9E8gavesignificantlylessneutralizationthanmAbMG-2C10at,10 mgm l
”1(lowerID50)
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(Rosa et al., 2007). Thus unlike immune serum, SC-
9A5 and SC-9E8 blocked infection downstream of cell
binding.
We examined virus entry further by immunofluorescence
(Fig. 4), using release of the abundant tegument component
encoded by ORF75c (Gaspar et al., 2008; Supplementary
Fig. S1, available in JGV Online) as a marker of virion
membrane fusion. The ORF75c of untreated virions was
rapidly transported to the cellnucleus. Its increase instaining
after fusion presumably reflects that not all the ORF75c in
intact virions is accessible to antibody. When fusion was
blocked with concanamycin A, virions were retained in late
endosomes,asshownbyORF75cco-localizingwithLAMP-1.
SC-9A5 and SC-9E8 caused a similar retention. Therefore,
they blocked membrane fusion rather than an upstream
event such as virion transport to late endosomes.
Effect of antibody on cell binding by recombinant
gB
We next established how SC-9A5 and SC-9E8 affected the
interaction of gB with its cellular ligands. We have
previously shown that gB-N fused to IgG Fc binds to cell
surfaces (Gillet et al., 2007b). Across a range of cell types,
gB-N-Fc bound most cells weakly and a minor population
strongly, suggesting two distinct modes of binding: Fig.
5(a) shows NMuMG cells and Fig. 5(b) shows spleen cells.
Surprisingly, the strongly bound cell subset had lower
forward and side scatter, consistent with apoptosis. IgG Fc
alone did not bind to these cells, and an Fc fusion of gp70
short consensus repeats (SCRs) 1 and 2, which binds to
heparan sulfate (HS) (Gillet et al., 2007b), bound poorly.
Therefore, the strong binding was specific to gB-N-Fc. The
fact that these cells were apoptotic was confirmed by co-
staining with annexin V: the cells that stained strongly by
gB-N-Fc were all annexin V
+ (Fig. 5c).
The HSV-1 gB binds to lipids via its fusion loops (Hannah
et al., 2009). Protease digestion of NMuMG cells (Fig. 6a)
abolished their general weak staining by gB-N-Fc, but not
the strong staining of apoptotic cells, consistent with these
being distinct interactions and with the latter involving a
non-protein, presumably lipid ligand. In order to distin-
guish the two binding activities of gB-N-Fc more clearly,
we used SF9 insect cells as a target likely to lack any gB
protein ligand. gB-N-Fc staining of SF9 insect cells (Fig.
6b) was completely protease-resistant, implying that it was
due entirely to lipid binding. That it involved the gB fusion
loops was confirmed by mutating fusion loops 1 or 2 (see
Fig. 1e). Mutations L1V1 and L2 abolished all staining of
SF9 cells (Fig. 6d) and also the strong staining of apoptotic
NMuMG cells (Fig. 6c), but not the general weak staining
of NMuMG cells. Mutation L1V3 had a similar effect (data
not shown). Mutation L1V2 could not be tested due to
poor expression as gB-N-Fc.
mAbs SC-9A5 and SC-9E8 inhibited gB-N-Fc binding to
neither SF9 (Fig. 6e) nor NMuMG cells (Fig. 6f). Therefore,
their neutralization did not involve an inhibition of gB
binding to either its fusion loop-independent protein
ligand or its fusion loop-dependent lipid ligand.
It is important to note that MuHV-4 does not actually
infect SF9 or apoptotic cells. Infection requires HS
engagement (Gillet et al., 2007b), and apoptotic and SF9
cells express little HS. gB binding presumably occurs only
downstream in infection, as virions without HS binding
also lack cell binding (Gillet et al., 2009a). The fusion loop-
dependent binding of gB-N-Fc to SF9 and apoptotic cells
but at .10 mgm l
”1neutralizationwassignificantlymorecomplete(P,10
”5).(b) SC-9A5 andSC-9E8neutralize both fibroblastand
epithelial cell-derived virions. BAC
+ MuHV-4 (0.1 p.f.u. per cell) grown in either BHK-21 fibroblasts or NMuMG epithelial cells was
incubated with antibody then used to infect BHK-21 cells as in (a). Despite a low ID50, MG-2C10 fails to neutralize BHK-21 cell-
derived virions completely and NMuMG cell-derived virions at all because its epitope is variably masked by O-linked glycans. Each
point shows the mean±SEM oftwo experiments. (c) The SC-9A5/SC-9E8 epitope is located in the N-terminal half ofgB. 293T cells
weretransfectedwithglycosyl-phosphatidyl-inositol(GPI)-linkedgBfragmentscomprisingtheentireextracellulardomain(gB),itsN-
terminal 423 aa residues (gB-N) or empty vector (grey histogram), then stained with gB-specific mAbs and analysed by flow
cytometry. BN-1A7 recognizes an epitope in gB-N; MG-1A12 recognition requires the full-length gB extracellular domain. (d) SC-
9A5 and SC-9E8 recognize identical or overlapping epitopes distinct from those recognized by neutralizing IgMs MG-2C10 and
BH-6B5. MuHV-4-infected BHK-21 cells (2 p.f.u. per cell, 18 h) were incubated with the indicated blocking mAbs, and then the
indicatedIgG2a stainingmAbsfollowedbyanIgG2a-specific,fluorescentlylabelledsecondaryantibody.Thecellswerethenanalysed
for fluorescence by flow cytometry. ‘+’5Reduced binding of the staining mAbs; ‘”’5no effect. (e) Mutagenesis of the putative
MuHV-4 gB fusion loops. Fusion loops 1 and 2 of the HSV gB and the homologous regions of the MuHV-4 gB are shown, together
with three mutations we introduced into loop 1 (L1V1, L1V2 and L1V3) and one mutation we introduced into loop 2 (L2). The
cartoons show the published structure of the HSV-1 gB ectodomain (Heldwein et al., 2006) and the predicted structure of the
corresponding amino acid residues 60–680 of the MuHV-4 gB ectodomain. The positions of the mutated MuHV-4 gB residues and
the homologous HSV-1 gB residues are shown in green for L1V1, in blue for L1V2, in orange for L1V3 and in red for L2. (f) SC-9A5
and SC-9E8 bind close to gB fusion loop 1. 293T cells were transfected with GPI-linked wild-type (WT) gB, one of the mutants
(L1V1, L1V2, L1V3 or L2) or left untransfected (UT), then stained with gB-specific mAbs and analysed by flow cytometry. L1V3 was
introduced into full-length gB. L1V1, L1V2 and L2 expressed poorly in this form and so were introduced into gB-N. Each was
matched with the appropriate WT (gB or gB-N). mAbs SC-9A5 and SC-9E8 recognized L1V1 and L1V2 significantly less well than
W T ,L 1 V 3o rL 2( P,10
”5 by t-test). Equivalent data were obtained in two further experiments.
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http://vir.sgmjournals.org 2023Fig. 2. SC-9A5 and SC-9E8 recognize pre-fusion gB. (a) NMuMG cells were incubated with MuHV-4 (3 p.f.u. per cell, 2 h,
4 6C), washed and then either fixed immediately or first further incubated (2 h, 37 6C) to allow virion endocytosis. The cells
were then stained with mAbs SC-9A5, SC-9E8, BN-1A7 or MG-1A12 (green). BN-1A7 recognizes only pre-fusion gB;
MG-1A12 recognizes only post-fusion gB. The cells were also stained for LAMP-1 (red) and counter-stained with DAPI (blue).
Equivalent data were obtained in two further experiments. In this and all subsequent figures, the data shown are representative
of at least 100 cells examined. Note that MuHV-4 plaque titres underestimate virion numbers 10–100-fold. (b) Infections and
stainings were performed as in (a), except that the cells were incubated with 1 mM concanamycin A before adding virus
(2 h, 37 6C), as well as during virus binding and endocytosis, so as to raise the endosomal pH and prevent virion membrane
fusion. Equivalent data were obtained in two further experiments.
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+
virions (3 p.f.u. per cell) were pre-incubated with mAbs, MuHV-4-immune serum or heparin (2 h, 37 6C) before binding to
NMuMG cells (2 h, 4 6C). Unbound virions were removed by washing and the cells analysed immediately for eGFP
fluorescence by flow cytometry. To assess virus entry (right panel), BAC
+ MuHV-4 (0.1 p.f.u. per cell) was pre-incubated as
above then added to NMuMG cells, which were analysed for viral eGFP expression after overnight incubation (37 6C) with
100 mg phosphonoacetic acid ml
”1. The bars show mean±SEM values from two independent experiments. (b) SC-9A5 and
SC-9E8 neutralize both cell-bound and cell-free virions. To neutralize cell-free virions, BAC
+ MuHV-4 (0.3 p.f.u. per cell) was
pre-incubated with mAbs or immune serum (2 h, 4 6C), then bound to BHK-21 cells (2 h, 4 6C). Unbound virions were
removed by washing with PBS. To neutralize cell-bound virus, BHK-21 cells were incubated with BAC
+ MuHV-4 (0.3 p.f.u. per
cell, 2 h, 4 6C), washed, incubated with mAbs or immune serum (2 h, 4 6C), then washed again. All cells were then incubated
overnight (37 6C) with 100 mg phosphonoacetic acid ml
”1 and analysed for viral eGFP expression by flow cytometry. For
SC-9A5 and SC-9E8 ID50 values for either method differed ,threefold; for immune serum the difference was .30-fold. (c)
SC-9A5 and SC-9E8 neutralize MuHV-4 for fibroblast, epithelial cell and macrophage infections. EF1a-eGFP
+ MuHV-4 was
pre-incubated with mAbs or MuHV-4 immune serum (2 h, 37 6C), then added to BHK-21 (0.1 p.f.u. per cell), NMuMG
(0.1 p.f.u. per cell) or RAW-264 cells (4 p.f.u. per cell). All cells were incubated overnight (37 6C) with 100 mg
phosphonoacetic acid ml
”1 and analysed for viral eGFP expression by flow cytometry. Each point shows the mean±SEM of
two experiments.
Gammaherpesvirus neutralization
http://vir.sgmjournals.org 2025may reflect lipid similarities between their plasma mem-
branes and the late endosomal membranes with which
MuHV-4 normally fuses. For example, while late endo-
somes are relatively deficient in the phosphatidyl serine
displayed by apoptotic cells (Balasubramanian & Schroit,
2003), they are enriched for another anionic lipid, lysobis-
phosphatidic acid (Kobayashi et al., 1998).
Tracking the gB conformation of SC-9A5-
neutralized virions
MuHV-4 capsid (Gillet et al., 2008a) and tegument (Fig.
4) release from late endosomes is associated with gB
switching its antigenicity from BN-1A7
+MG-1A12
2 to
BN-1A7
2MG-1A12
+ (Fig. 2). Virions neutralized by mAb
SC-9A5 were transported to late endosomes but remained
BN-1A7
+ (Fig. 7a). To our surprise they nonetheless
gained MG-1A12 reactivity (Fig. 7b). Therefore, although
the post-fusion state of BN-1A7
2MG-1A12
+ was not
achieved, consistent with ORF75c release being blocked
(Fig. 4), gB did not remain in its pre-fusion form. We
conclude that mAb SC-9A5 prevents membrane fusion
not by blocking the initiation of gB conformation
changes, but by blocking their resolution to a stable
post-fusion state (Fig. 7c).
Limitations on gB-directed neutralization
The MuHV-4 gB associates with gH/glycoprotein (gL)
(Gillet & Stevenson, 2007b), and its N terminus hides an
epitope on the gH/gL extracellular domain (Gillet &
Stevenson, 2007a). This association also restricts gB-directed
neutralization (Gillet et al., 2009b), and gL
2 virions were
more susceptible than gL
+ to neutralization by SC-9E8 and
SC-9A5 (Fig. 8). Deleting the gB N terminus also increased
gB susceptibility to these mAbs. While not compromising
MuHV-4 replication, this disrupts the interaction between
the gB and gH/gL extracellular domains (Gillet & Stevenson,
2007a). Therefore, despite the neutralization of wild-type
(WT) virions by SC-9E8 and SC-9A5 being substantial, it
was still restricted in part by the interaction between gB
and gH/gL.
Fig. 4. SC-9A5 and SC-9E8 prevent release of the ORF75c tegument protein. MuHV-4 (3 p.f.u. per cell) was left untreated
(nil) or pre-incubated (2 h, 37 6C) with 400 mg SC-9A5 (IgG3) or SC-9E8 (IgG2a)m l
”1 before binding to NMuMG cells
(2 h, 4 6C). For concanamycin A treatment, cells were incubated with 1 mM concanamycin A before adding virus (2 h, 37 6C)
and during binding (2 h, 4 6C). Unbound virions were then removed by washing and the cells either fixed immediately or after a
further incubation (2 h, 37 6C) in the presence or absence of antibodies and drug. The cells were stained with the ORF75c-
specific IgG1 BN-8C3 (green), a LAMP-1-specific mAb (red) and DAPI (blue). All images were taken with the same confocal
settings. Incubating virions with the non-neutralizing gB-specific IgG2a BN-1A7 or incubating cells with DMSO alone had no
effect (not shown). Equivalent data were obtained in three further experiments.
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The central role of gB in herpesvirus cell binding and
membrane fusion should make it a good neutralization
target. However, MuHV-4 seems to resist gB-directed
neutralization. gB glycosylation (Gillet & Stevenson,
2007a), the gB-gH/gL association (Gillet & Stevenson,
2007b) and post-endocytic glycoprotein conformation
changes (Gillet et al., 2008a) all provide protection.
SC-9E8 and SC-9A5 are nevertheless the most potent
MuHV-4-neutralizing mAbs identified to date, and their
capacity for complete neutralization places their epitope
amongthemostvulnerableidentifiedforany herpesvirusgB.
We aimed here to understand how this neutralization works.
Most neutralizing antibodies compete with a cellular ligand
for virus binding (Knossow & Skehel, 2006). SC-9A5 and
SC-9E8 interfered instead with the fusion-associated gB
conformation change. This is defined by gB antigenic
changes that accompany capsid and tegument release. The
MuHV-4 gB conformation change seems to be substantial
since mAbs recognizing multiple distinct epitopes show
similar changes in recognition. The HSV-1 gB (Heldwein
et al., 2006) provides some analogous structural informa-
tion, but its pre-fusion form and conformation change
remain unidentified. Thus, the MuHV-4 gB switch from BN-
1A7
+MG-1A12
2 pre-fusion to BN-1A7
2MG-1A12
+ post-
fusion is very different to a local change within the post-fusion
Fig. 5. Strong staining of apoptotic cells by gB-N-Fc. (a) NMuMG cells were trypsinized, incubated overnight (37 6C) on Petri
dishes, then removed by vigorous pipetting and stained with Fc fusion proteins and analysed by flow cytometry. Gate 1
corresponds to apoptotic cells (.95% annexin V
+) and gate 2 to viable cells (,10% annexin V
+). For gB-N-Fc staining of
ungated cells, 2.5% of cells were in region R2 and those in R1 had median fluorescence intensity (MFI)519.4; gate 1 had
7.6% of cells in R2 with R1 MFI59.1; gate 2 had 0.3% of cells in R2 with R1 MFI520.3. For ORF4:SCR 1-2-Fc staining,
ungated cells had MFI588.4, gate 1 MFI59.8 and gate 2 MFI5189.3. (b) The spleen of a naive mouse was disrupted into a
single-cell suspension and red cells removed by centrifugation on Ficoll. The remaining cells were incubated with a blocking
antibody for FccRII/III (CD16/CD32) and then stained with Fc fusions and analysed by flow cytometry as in (a). B cells were
identified by staining for CD19. Again gate 1 corresponds to apoptotic cells and gate 2 to viable cells. For gB-N-Fc staining
of ungated cells, R1 contained 38.9% of CD19
+ cells and R2 45.1%; gate 1 had 0.9% of CD19
+ in R1 and 95.8% in R2;
gate 2 had 82.9% of CD19
+ in R1 and 1.5% in R2. For ORF4:SCR 1-2-Fc staining, ungated cells had 43.2% of CD19
+ in
R1 and 49.5% in R2; gate 1 had 95.2% of CD19
+ in R1 and 2.0% in R2; gate 2 had 0.7% of CD19
+ in R1 and 96.6% in
R2. (c) NMuMG cells were co-stained with gB-N-Fc and with annexin V, then analysed by flow cytometry. The percentage of
cells in each quadrant is shown.
Gammaherpesvirus neutralization
http://vir.sgmjournals.org 2027Fig. 6. gB-N-Fc shows two distinct modes of cell binding. (a) NMuMG epithelial cells were incubated or not with proteinase K
(100 mgm l
”1, 15 min, 37 6C), then washed five times in PBS, stained with Fc fusions of the HS-binding domains of gp70
(ORF4) or gB-N as indicated, and analysed by flow cytometry. Protease treatment completely abolished ORF4:SCR1-2-Fc
staining. For gB-N-Fc staining it reduced the MFI of cells in R1 from 6.2 to 1.7, while the percentage of cells in R2 increased
from 1.4 to 6.3. (b) SF9 insect cells were incubated or not with proteinase K as in (a), then stained with Fc alone (filled
histograms) or with gB-N-Fc (open histograms), and analysed by flow cytometry. Staining by gB-N-Fc was increased by
protease treatment. (c) NMuMG cells were stained with Fc fusion proteins as indicated. ORF4:SCR1-2 binds to HS; M7:
1-151 does not bind to NMuMG cells; L1 and L2 are fusion-loop mutants of gB-N as described in Fig. 1(e). The gB-N mutants
were expressed less well than WT gB-N-Fc, so the immunoblot compares L1 and L2 supernatants with dilutions of the WT,
probed for human IgG Fc. The flow cytometry profiles show NMuMG cell staining with the same supernatants (filled histogram)
versus an Fc only control (open histogram). The L1 and L2 mutants lacked the minor, strongly stained population seen with all
dilutions of WT gB-N-Fc, but preserved the weaker staining of all the cells. Thus, the L1 mutant had 0% of cells in R2 with R1
MFI510.6, while the equivalent amount of WT (1/8 dilution) had 4.56% of cells in R2 with R1 MFI55.9. The L2 mutant had 0%
of cells in R2 with R1 MFI58.2, while the equivalent amount of WT (1/2 dilution) had 6.4% of cells in R2 with R1 MFI515.1.
(d) SF9 insect cells were stained with matched concentrations of gB-N-Fc, the L1 or L2 mutants or Fc only, then analysed
by flow cytometry. In contrast to NMuMG cells, the gB-N-Fc staining of SF9 cells was completely fusion loop-dependent.
(e) gB-N-Fc was incubated with mAbs SC-9A5 or SC-9E8, then used to stain SF9 cells. Flow cytometry showed no loss of this
binding, which in (d) was fusion loop-dependent. Nor was it blocked by serum from MuHV-4-infected mice, but serum from
MuHV-4-infected mice boosted with a vaccinia virus recombinant expressing GPI-linked gB-N (boosted serum) significantly
reduced gB-N-Fc binding (P,10
”5 by t-test). (f) gB-N-Fc was incubated with mAbs SC-9A5 or SC-9E8, then used to stain
NMuMG cells. Flow cytometry showed no reduction in this binding, which in (c) was fusion loop-independent.
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2028 Journal of General Virology 92Fig. 7. SC-9A5 arrests gB in an intermediate state between pre- and post-fusion conformations. Infections, drug treatments
and antibody treatments were as for Fig. 4. In (a) the cells were stained with the pre-fusion gB-specific IgG2a BN-1A7 and in (b)
with the post-fusion gB-specific IgG2a MG-1A12 (green). The cells were also stained for LAMP-1 (red) and with DAPI (blue).
Treating cells with DMSO alone had no effect (not shown). Equivalent data were obtained in two further experiments. (c) This
schematic diagram summarizes the progress of antigenic changes in gB during virion entry, and the distinct blocks to this
progress effected by concanamycin A and antibody-mediated neutralization. We hypothesize that the BN-1A7
+MG-1A12
+
state of neutralized virions reflects their gB being able to switch reversibly between its pre- and post-fusion conformations.
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et al., 2010).
VSV-G (Roche et al., 2008) provides a more useful
comparison, as both its pre- and post-fusion forms are
known. For example, that mAbs against gB-N specifically
recognize pre-fusion gB is consistent with the equivalent
region of VSV-G being apical on the pre-fusion trimer and
morecaudalpost-fusion(Roche etal.,2007).Thecapacity of
VSV-G to switch reversibly between its pre- and post-fusion
forms independent of actual membrane fusion (Roche et al.,
2008) suggested that the BN-1A7
+MG-1A12
+ state of
SC-9A5-neutralized gB might similarly reflect an equilib-
rium between its pre-fusion (BN-1A7
+MG-1A12
2)a n d
post-fusion (BN-1A7
2MG-1A12
+) forms. (Somewhat less
BN-1A7 staining than extracellular virions, and somewhat
less MG-1A12 staining than post-fusion virions, would be
hard to discern by immunofluorescence; whereas increases
in staining from a background of zero were very obvious.)
An intermediate form of gB simultaneously expressing the
BN-1A7 and MG-1A12 epitopes seemed a less likely
explanation, as the VSV-G model predicts intermediates to
be both unstable and very different to either pre- or post-
fusion gB. SC-9A5 did not cause a partial fusion block, since
it inhibited tegument release better than concanamycin A,
which kept gB completely BN-1A7
+MG-1A12
2. Rather
it arrested entry at a qualitatively distinct point. Thus, gB
may start to switch conformation reversibly before actual
fusion occurs.
The MG-1A12 epitope could in theory have been revealed
by displacing another virion glycoprotein. However, none
of gL
2, gp150
2, gp70
2, gp48
2 and ORF28
2 virions is
constitutively MG-1A12
+; a role for gH would seem
unlikely given the redundancy of gL; and gM/gN cannot
protrude far from the virion membrane (May et al., 2005).
We conclude that MG-1A12 epitope display reflected a
change in gB itself. Thus, SC-9E8/SC-9A5 did not prevent
the initiation of gB conformation changes but rather their
resolution. The VSV-G conformation switch implies a
transient dissociation of the pre-fusion trimer (Roche et al.,
2008), so SC-9A5/SC-9E8 might for example prevent the
reassociation of post-fusion gB monomers.
While SC-9E8 and SC-9A5 neutralized WT virions, they
were even more effective against virions lacking gL or the
gB N terminus (gBD2-30). The difference was not in
maximal neutralization, but in virion susceptibility to a
given antibody dose. gBD2-30 and gL
2 virions both have
normal levels of gB in an apparently normal conformation
(Gillet & Stevenson, 2007a; Gillet et al., 2009b). However,
the extracellular link between gB and gH/gL is altered. The
gB N terminus is normally displaced by gH/gL dissociation
in late endosomes (Gillet et al., 2008b); by making this
change constitutive, the gBD2-30 and gL
2 mutations could
increase gB exposure to antibody. That higher antibody
doses were sufficient to neutralize WT virions suggested
that the interaction between gH/gL and gB is dynamic.
However, this needs further analysis. The key point is that
the SC-9E8/SC-9A5 epitope is relatively accessible even on
WT virions. Targetting it could therefore provide a general
route to gammaherpesvirus neutralization.
METHODS
Cells. BHK-21 fibroblasts (American type culture collection CCL-
10), NMuMG epithelial cells (CRL-1636), 293T cells (CRL-11268)
and RAW-264 macrophages (TIB-71) were grown in Dulbecco’s
modified Eagle’s medium with 2 mM glutamine, 100 U penicillin
ml
21, 100 mg streptomycin ml
21 (PAA Laboratories) and 10% FCS
(complete medium) (PAA Laboratories). SF9 cells were grown in
Schneider’s insect cell medium (Sigma-Aldrich), supplemented as
above.
Plasmids. Expression plasmids for glycosyl-phosphatidyl-inositol
(GPI)-linked and human IgG1 Fc-linked forms of the gB extracellular
domain and its N-terminal 423 aa residues (gB-N) have been
described (Lopes et al., 2004; Gillet et al., 2007b). The GPI linkage
facilitates gB expression at the cell surface; full-length recombinant gB
is antigenically indistinguishable (based on staining with .50 mAbs)
but is retained in the endoplasmic reticulum. We used overlap PCR to
Fig. 8. Susceptibility to gB-directed neutralization of WT, gL
” and gBD2-30 virions. WT virions or those lacking gL (gL
”) or the
N-terminal 30 residues of the mature gB (gBD2-30) were incubated with gB-specific mAbs as shown then added to BHK-21
cells. The cells were scored for virus infection by flow cytometric assay of viral eGFP after overnight incubation (37 6C) with
100 mg phosphonoacetic acid ml
”1. SC-9A5 and SC-9E8 neutralized the gL
” and gBD2-30 mutants significantly better than
WT (P,10
”5 by chi-squared test, comparing the proportions of eGFP
+ and eGFP
” cells for at least three antibody dilutions).
BH-6B5 neutralized only the gL
” mutant better (P,10
”5). The gBD2-30 mutant lacks the epitope recognized by mAb
MG-2C10, but why the gL
” mutant was less well neutralized by MG-2C10 than the WT (P,10
”5) was unclear. Each point
shows the mean±SEM of two experiments
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residues 127–128 WR changed to AA5gB L1V1; residues 123–125
QLT changed to AAA5gB L1V2; residues 130–132 LTT changed to
AAA5gB L1V3) and fusion loop 2 (amino acid residues 215–217 FYR
changed to AAA5gB L2). These mutations were confirmed by DNA
sequencing. The expression plasmids were transfected into 293T cells
using Lipofectamine 2000 (Invitrogen). The cells were analysed 48 h
later. IgG Fc fusion proteins were similarly harvested from transfected
293T cells. Fc fusions of gp70 short consensus repeats 1–2
(ORF4:SCR1-2-Fc), which binds to heparan sulfate (HS), and
gp150 amino acid residues 1–151 (M7:1-151-Fc), which has no
known ligand, have been described (Gillet et al., 2007b). IgG Fc with a
leader sequence was used as a control.
Viruses. All viruses were derived from a MuHV-4 bacterial artificial
chromosome (BAC) (Adler et al., 2000). gL
2 (Gillet et al., 2007c) and
gBD2-30 mutants (Gillet & Stevenson, 2007a) have been described
previously. The loxP-flanked BAC cassette was removed from viral
genomes by passage through NIH-3T3-CRE cells (de Lima et al.,
2004). For neutralization assays we used viral eGFP expression from
either the HCMV IE1 promoter in the BAC cassette or an intergenic
EF1a promoter (May & Stevenson, 2010). For binding assays we used
MuHV-4 with eGFP-tagged gM (May et al., 2008). Virus stocks were
grown in BHK-21 cells (de Lima et al., 2004). Cell debris was removed
by low speed centrifugation (1000 g, 10 min) and virions recovered
from supernatants by high speed centrifugation (38000 g, 90 min).
Virus stocks were titrated by plaque assay (de Lima et al., 2004). After
incubation with virus (2 h, 37 uC), BHK-21 cell monolayers were
overlaid with 0.3% carboxymethylcellulose (BDH) and 4 days later
fixed with 4% formaldehyde and stained with 0.1% toluidine blue
(Sigma-Aldrich).
Neutralization assays. For single-cycle infections, eGFP
+ viruses
were incubated with or without antibodies (2 h, 37 uC) then added to
cells (2 h, 37 uC) and cultured overnight in complete medium plus
phosphonoacetic acid (100 mgm l
21; Sigma-Aldrich) to prevent
secondary spread. The proportion of infected cells in each culture
was then determined by flow cytometry of eGFP expression. For
binding assays, gM-eGFP
+ virions were incubated with or without
antibodies (2 h, 37 uC) then added to cells (2 h, 4 uC) and the cells
analysed directly for green fluorescence by flow cytometry.
Antibodies. All MuHV-4-specific mAbs were derived from MuHV-
4-infected BALB/c mice. Staining was with hybridoma supernatants.
For neutralization assays, hybridoma supernatants were concentrated
by ammonium sulfate precipitation, dialysed against PBS and
quantified by Mancini assay (Mancini et al., 1965). Immune sera
were harvested .3 months post-infection and pooled from .five
mice. Rat anti-mouse LAMP-1 was from BD Biosciences.
Drug treatments. Concanamycin A (Sigma) stock solutions were
prepared at 150 mM in DMSO. Cells were treated with 1 mM
concanamycin A for 2 h at 37 uC prior to addition of virus, during
virus binding at 4 uC, and during virus endocytosis at 37 uC.
Treatment with identical volumes of DMSO served as a negative
control for concanamycin A treatments. Porcine intestinal heparin
was from Sigma.
Immunofluorescence. NMuMG cells were seeded overnight on to
glass coverslips. MuHV-4 virions (3 p.f.u. per cell) were bound to the
cells (2 h, 4 uC). The cells were then washed three times in ice-cold
PBS to remove unbound virions, and either fixed directly or first
incubated (2 h, 37 uC) in complete medium with or without drugs
and antibodies. After one wash in ice-cold PBS, cells were fixed by
adding ice-cold 4% formaldehyde in PBS and leaving at room
temperature (RT) for 30 min (mAb BN-8C3) or 1 h (all other mAbs).
The cells were then washed three times in PBS, permeabilized with
0.1% Triton X-100 (30 min, RT), blocked (overnight, 4 uC) with 3%
BSA/0.1% Triton X-100, then stained with primary mAbs (1 h, RT),
washed three times in PBS, stained with secondary Abs diluted in 5%
normal goat serum with 1 mg DAPI ml
21 (1 h, RT), washed three
times in PBS and once in H2O, and mounted in ProLong Gold
(Invitrogen). Secondary antibodies (goat anti-rat IgG or goat anti-
mouse IgG, IgG1, IgG2a or IgG3, labelled with Alexa Fluor 488, 568)
were all from Invitrogen. Images were acquired on a Leica TCS SP2
AOBS confocal laser scanning microscope with settings specific for
DAPI (excitation, 405 nm; recording, 410–470 nm), Alexa Fluor 488
(excitation, 488 nm; recording, 493–560 nm) and Alexa Fluor 568
(excitation, 561 nm; recording, 566–700 nm). Images were analysed
with ImageJ.
Flow cytometry. Transfected or MuHV-4-infected cells were
trypsinized and washed in PBS. Spleens were removed post-mortem
and homogenized into single-cell suspensions. Red cells were then
removed by centrifugation on Ficoll. Viral eGFP expression was
visualized directly. For specific staining, cells were incubated (1 h,
4 uC) with MuHV-4 glycoprotein-specific mAbs followed by fluor-
escein-conjugated rabbit anti-mouse IgG pAb (Dako Cytomation)
diluted in 5% normal rabbit serum, or with IgG-Fc fusion proteins
followed by fluorescein- or phycoerythrin-conjugated goat anti-human
IgG pAb (Sigma) diluted in 5% normal goat serum (1 h, 4 uC).
Unlabelled anti-CD16/32 Fc blocking mAb, phycoerythrin-conjugated
annexin V and fluorescein-conjugated anti-CD19 mAb were from BD
Biosciences. All samples were washed twice in PBS and analysed on a
FACScan or FACSCalibur (BD Biosciences).
Structure prediction. A 3D-structure prediction of the MuHV-4 gB
ectodomain (amino acid residues 32–730) was made using the
iterative threading assembly refinement (I-TASSER) server (Zhang,
2008; Roy et al., 2010). Structure models were analysed with PyMol
(DeLano Scientific LLC).
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